The SGYP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SGYP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The SGYP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View SGYP Detailed Price Forecast - CNN Money||View SGYP Detailed Summary - Google Finance|
|View SGYP Detailed Summary - Yahoo! Finance||View SGYP Stock Research & Analysis - Zacks.com|
|View SGYP Trends & Analysis - Trade-Ideas||View SGYP Major Holders - Barrons|
|View SGYP Call Transcripts - NASDAQ||View SGYP Breaking News & Analysis - Seeking Alpha|
|View SGYP Annual Report - CompanySpotlight.com||View SGYP OTC Short Report - OTCShortReport.com|
|View SGYP Fundamentals - TradeKing||View SGYP SEC Filings - Bar Chart|
|View Historical Prices for SGYP - The WSJ||View Performance/Total Return for SGYP - Morningstar|
|View the Analyst Estimates for SGYP - MarketWatch||View the Earnings History for SGYP - CNBC|
|View the SGYP Earnings - StockMarketWatch||View SGYP Buy or Sell Recommendations - MacroAxis|
|View the SGYP Bullish Patterns - American Bulls||View SGYP Short Pain Metrics - ShortPainBot.com|
|View SGYP Stock Mentions - StockTwits||View SGYP Stock Mentions - PennyStockTweets|
|View SGYP Stock Mentions - Twitter||View SGYP Investment Forum News - Investor Hub|
|View SGYP Stock Mentions - Yahoo! Message Board||View SGYP Stock Mentions - Seeking Alpha|
|View Insider Transactions for SGYP - SECform4.com||View Insider Transactions for SGYP - Insider Cow|
|View SGYP Major Holdings Summary - CNBC||View Insider Disclosure for SGYP - OTC Markets|
|View Insider Transactions for SGYP - Yahoo! Finance||View Institutional Holdings for SGYP - NASDAQ|
|View SGYP Stock Insight & Charts - FinViz.com||View SGYP Investment Charts - StockCharts.com|
|View SGYP Stock Overview & Charts - BarChart||View SGYP User Generated Charts - Trading View|
Synergy Pharmaceuticals Presents New Analyses Supporting the Use of TRULANCE® (plecanatide) in Two Patient Populations at the American College of Gastroenterology (ACG) Annual Scientific Meeting
Posted on Monday October 08, 2018
Synergy Pharmaceuticals Inc. (SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that the company will present new analyses that further reinforce the efficacy and safety of TRULANCE® (plecanatide) for adult patients with chronic idiopathic constipation (CIC) or irritable bowel syndrome with constipation (IBS-C), specifically in patients aged 65 and older and in patients using concomitant acid suppression medications such as proton pump inhibitors (PPIs) and/or histamine receptor antagonists (H2 blockers).
Is the Options Market Predicting a Spike in Synergy Pharmaceuticals (SGYP) Stock?
Posted on Wednesday October 03, 2018
Investors need to pay close attention to Synergy Pharmaceuticals (SGYP) stock based on the movements in the options market lately.
Synergy Pharmaceuticals Inc. (SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that two posters will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting, October 5-10, 2018, in Philadelphia, PA. Presentations include a poster detailing outcomes from a large post-hoc analysis evaluating the safety and tolerability of TRULANCE® (plecanatide) in chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in patients aged 65 and older compared to those in a younger cohort (≥18 to <65).
Synergy Pharmaceuticals Strengthens Coverage for TRULANCE® (plecanatide) with Key New Market Access Wins
Posted on Monday September 24, 2018
Synergy Pharmaceuticals Inc. (SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced several new formulary wins improving TRULANCE 2018 and 2019 coverage status across major U.S. Commercial, Medicare Part D and Managed Medicaid plans. “We are excited to announce several new formulary wins for TRULANCE, which we believe demonstrate our ongoing efforts to improve patient access and support future sales growth,” said Troy Hamilton, Chief Executive Officer of Synergy Pharmaceuticals Inc. “We believe the progress we’ve made towards strengthening market access is a result of our continued focus and commitment to optimizing the value of TRULANCE.